Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

This is the authors' abstract. We don't add key points for this paper.

Liraglutide reduces metabolic dysfunction, insulin resistance and lipotoxicity in the key metabolic organs in the pathogenesis of NASH. Liraglutide may offer the potential for a disease-modifying intervention in NASH.